RxDoctor Payments Data

Richard Otto, MD

Family Medicine · Georgetown, TXNPI 1730266420

Payments from drug & device makers

$10,747in general payments, 2019–2025

Across 657 payments — averaging $16.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$1K
  • AbbVie$848
  • Otsuka America Pharmaceutical, Inc.$743
  • Amgen$670
  • Lilly USA, LLC$659
  • plus $5K from 52 others

What the payments were for

  • Food & beverage$10,60499%
  • Education$1431%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,747 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$149,260
Medicare patients
455
Services billed
11,121

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide33$40,341
JanuviaSitagliptin Phosphate18$27,497
JardianceEmpagliflozin20$23,811
EliquisApixaban32$23,216
RexultiBrexpiprazole12$16,426
Tresiba Flextouch U-100Insulin Degludec26$14,384
MyrbetriqMirabegron18$11,544
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen251$8,610
Tresiba Flextouch U-200Insulin Degludec11$6,753
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$5,531
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/712$3,565
Levothyroxine Sodium240$3,140
SymbicortBudesonide/Formoterol Fumarate12$2,692
Rosuvastatin Calcium185$2,061
SynthroidLevothyroxine Sodium41$2,011

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,268$40,34133 claims
MerckJanuvia$56$27,49718 claims
Boehringer IngelheimJardiance$431$23,81120 claims
PfizerEliquis$575$23,21632 claims
Otsuka America Pharmaceutical, Inc.Rexulti$743$16,42612 claims
Astellas Pharma US IncMyrbetriq$247$11,54418 claims
AstraZenecaSymbicort$1,179$2,69212 claims
AbbVieSynthroid$848$2,01141 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Georgetown

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →